Alluvi, previously BI 4744, presents a notable development in weight loss care. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling results in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/